A report by sky news today (26th March 2017) says that a £1.5m pledge for UK children who do not respond to traditional therapies will be spent on them receiving personalised treatments for the first time.
‘Children with Cancer UK’ is providing £1.5M to support initial stages of a programme which will develop a precise and effective cancer treatment. As well as with low aggressive side effects for children.
This will give the 300 children with cancer in the UK who don’t respond to traditional therapies, including chemotherapy or radiotherapy, a more hopeful alternative treatment.
Professor Paul Workman, Chief executive of the Institute of Cancer Research, said:
“This funding from Children with Cancer UK is fantastic; it’s going to be transformative. It will allow us to do personalised, individualised treatment of cancer patients targeted at the actual DNA changes in the individual patient. This will be kinder to the body and more effective.”
This treatment is already available to adults, however, it has never before been available to children anywhere in the world.
Professor Workman also said:
“What we aim to do is be able to make the test systematically available throughout the UK. We hope that the NHS and pharmaceutical companies will embrace the new treatment and roll it out.”
For further information, please see:
Dr Cohen started her working life as a research scientist and lecturer with over 100 peer-reviewed scientific publications.
She followed a classical scientific career until she left mainstream science in 2000 (which coincided with the birth of her first daughter) to establish the Life Science Communications company, Euroscicon Ltd.
Euroscicon Ltd was her first company (which she sold in 2016).
In 2013 she was diagnosed with Cancer and set up Cancer Care Parcel
She also works with and establishes businesses and charities which benefit local, national and international communities via her company – The Pein Consultancy Ltd